The peptide appears to play an important role in vascular dysregulation, and reducing the effect of ET-1 in glaucomatous eyes can potentially have beneficial effects on ocular perfusion, preventing vasospasm and the risk of retinal ischemia [17,18]. Here, EDN1 is linked to retinal ischemia.